arketis 20 mg tablett
medochemie limited - paroksetiin - tablett - 20mg 10tk; 20mg 98tk; 20mg 56tk; 20mg 14tk; 20mg 60tk; 20mg 28tk; 20mg 180tk; 20mg 120tk; 20mg 90tk; 20mg 30tk
paroxetine aurobindo 30mg õhukese polümeerikattega tablett
aurobindo pharma limited - paroksetiin - õhukese polümeerikattega tablett - 30mg 30tk; 30mg 100tk; 30mg 250tk; 30mg 14tk; 30mg 50tk; 30mg 28tk; 30mg 10tk; 30mg 20tk; 30mg 98tk; 30mg 56tk
seroxat õhukese polümeerikattega tablett
glaxosmithkline (ireland) limited - paroksetiin - õhukese polümeerikattega tablett - 20mg 100tk; 20mg 30tk
rexetin õhukese polümeerikattega tablett
gedeon richter plc. - paroksetiin - õhukese polümeerikattega tablett - 20mg 30tk
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
seroxat õhukese polümeerikattega tablett
ideal trade links uab - paroksetiin - õhukese polümeerikattega tablett - 20mg 14tk; 20mg 30tk; 20mg 28tk
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunosupressandid - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosupressandid - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosuppressants, valikuline immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).